The treatment options for spinal cord injury remain limited, with few approved spinal cord injury therapies available. At present, STEMIRAC is the only approved SCI treatment, and it is offered exclusively in Japan. There is an urgent need for targeted solutions that can enhance patient outcomes and support functional recovery. The SCI therapeutic pipeline is steadily growing, with promising candidates such as Kringle Pharma’s KP-100IT, Neuroplast’s Neuro-Cells, Mitsubishi Tanabe Pharma America’s MT-3921, AbbVie’s Elezanumab, Pharmazz’s PMZ-1620, Neurofix’s NFX88, NervGe n Pharma’s NVG-291, ReNetX Bio’s AXER-204, and NurExone’s ExoPTEN, among others. The introduction ...
